Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13080690 | 1.00 | SLC6A9 (0.64) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL13080691 | 1.00 | SLC6A9 (0.64) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL13080692 | 1.00 | SLC6A9 (0.64) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL13079592 | 1.00 | SLC6A9 (0.64) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL13079594 | 1.00 | SLC6A9 (0.64) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL13050312 | 0.96 | SLC6A9 (0.69) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL13050299 | 0.96 | SLC6A9 (0.69) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL13050304 | 0.96 | SLC6A9 (0.69) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL13050309 | 0.96 | SLC6A9 (0.69) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL13050308 | 0.96 | SLC6A9 (0.69) | SLC6A9SLC6A4HRH3SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | GPR119, CPT1A, GLS2 | SLC6A9 2998/4885SLC6A4 1007/4885HRH3 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.